普罗帕酮与胺碘酮治疗阵发性室上性心律失常的临床研究

Analysis of clinical efficacy and safety of propafenone and amiodarone in the treatment of aroxysmal supraventricular tachycardia

目的比较普罗帕酮与胺碘酮治疗阵发性室上性心律失常的临床疗效及安全性。方法 2015年1月至2016年6月就诊于我院治疗室性心律失常100例随机分为观察组和对照组。对照组给予胺碘酮联合琥珀酸美托洛尔治疗;观察组给予普罗帕酮联合琥珀酸美托洛尔;疗程均为6个月。观察组和对照组治疗前比较,差异无统计学意义(P>0.05)。结果普罗帕酮联合琥珀酸美托洛尔比胺碘酮联合琥珀酸美托洛尔在转复时间、6个月复发率中有明显优势;2组均无严重不良反应。结论普罗帕酮联合琥珀酸美托洛尔治疗室性心律失常安全、有效,值得推广。

Objective To compare the clinical efficacy and safety of propanone and amiodarone in the treatment of paroxysmal supraventricular tachycardia（PSVT）.Methods One-hundred patients with PSVT selected from January 2015 to June 2016 in our hospital were randomly divided into observation group（50 cases）and control group（50 cases）.The control group was treated with amiodarone combined metoprolol succinate.The observation group was treated with propafenone combined metoprolol succinate.The course of treatment was 6 months for both groups.The conversion time and recurrent frequency and adverse reaction of the two groups were observed and compared.All data were analyzed by SPSS 18.0,ttest andχ~2 test were used for analysis statistically.Results There were significant difference between two groups in conversion time（8.7±1.89）vs（19.80±2.35）and recurrent frequency（1.00±0.94）vs（2.70±2.00）（P〈0.05）,The conversion time and recurrent frequency of the observation group was shorter and less than that of the control group.No serious adverse reactions were found in two groups.Conclusion Propafenone combined metoprolol succinate for the treatment of PSVT is safe and effective,and the method deserves to be popularized.